5 Key Takeaways

• 1

  A next-generation sequencing (NGS) assay may enhance early identification of patients with MGUS and SMM at high risk for AL amyloidosis.

• 2

  The study demonstrated NGS's ability to detect clonal immunoglobulin lambda sequences without CD138 cell selection.

• 3

  NGS identified clonal populations in 96.1% of unselected MNC RNA samples and 92.3% of CD138-selected samples.

• 4

  High concordance was observed between NGS and Sanger sequencing, with 91.3% agreement in clonal identification.

• 5

  The findings suggest NGS could streamline patient assessment and monitoring in hematology and oncology settings.